Premium
MiR‐143‐3p suppresses cell proliferation, migration, and invasion by targeting Melanoma‐Associated Antigen A9 in laryngeal squamous cell carcinoma
Author(s) -
Han Liang,
Tang Mingming,
Xu Xinjiang,
Jiang Bin,
Wei Yingze,
Qian Hongyan,
Lu Xueguan
Publication year - 2019
Publication title -
journal of cellular biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 165
eISSN - 1097-4644
pISSN - 0730-2312
DOI - 10.1002/jcb.27084
Subject(s) - downregulation and upregulation , cancer research , western blot , carcinogenesis , cell growth , microrna , cell , biology , cancer , medicine , gene , biochemistry , genetics
Previously we found that melanoma‐associated antigen‐A9 (MAGE‐A9) was a significantly upregulated biomarker in laryngeal squamous cell carcinoma (LSCC). A high expression of MAGE‐A9 indicates an unfavorable survival outcome, and the MAGE‐A9 expression level is an independent prognostic factor of LSCC. To explore the mechanism of MAGE‐A9 upregulation, several predicted regulatory microRNAs were screened and validated in LSCC cells. In the current study, we found that miR‐143‐3p (MAGE‐A9 related miRNAs) expression levels correlated negatively with the MAGE‐A9 protein expression in LSCC tissues. Dual‐luciferase reporter assays and Western blot analysis revealed MAGE‐A9 to be a direct target of miR‐143‐3p. Furthermore, a series of in vitro gain‐ and loss‐of‐function assays revealed that miR‐143‐3p inhibited LSCC cell proliferation, migration, and invasion. Also, miR‐143‐3p suppressed LSCC tumorigenesis in vivo. These effects were clinically relevant, as a lower expression of miR‐143‐3p occurred in severer clinical stages and represented poor overall survival in patients with LSCC. Taken together, these results suggest that downregulation of miR‐143‐3p contributes to tumor progression through upregulation of MAGE‐A9. The expression level of these two key molecules maintained LSCC progression, thus, highlighting the potential of miR‐143‐3p as a therapeutic target for human LSCC.